KRAS Q61 in PDAC (rare vs G12) — no approved drug; chemo + clinical trial.
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-Q61-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | KRAS Q61X |
| Disease | DIS-PDAC |
| ESCAT tier | IV |
| Evidence summary | KRAS Q61 in PDAC (rare vs G12) — no approved drug; chemo + clinical trial. |
Notes
ESCAT IV. FLAG: dedicated BIO-KRAS-Q61X would improve granularity.
Used By
No reverse references found in the YAML corpus.